Response Based Treatment for Children With Unresectable Localized Soft Tissue Sarcoma

Response-based Treatment for Children With Unresectable Localized Soft Tissue Sarcomas

Status

UNKNOWN

Phases

Phase 2

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT02784015

Enrollment

Registered

2016-05-26

Start date

2016-05-31

Completion date

2023-05-31

Last updated

2018-09-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Unresectable Localized Soft Tissue Sarcoma

Brief summary

To evaluate the treatment outcome of unresectable soft tissue sarcoma using response based treatment

Detailed description

Response after initial chemotherapy is one of the important prognostic factor in many cancers. In this study, treatment will be tailored according to the treatment responses which are assessed by tumor volume reduction, necrosis rate or residual fludeoxyglucose (FDG) uptake in positron emission tomography (PET) scan.

Interventions

DRUGCisplatin

DRUGEtoposide

DRUGDoxorubicin

DRUGCyclophosphamide

DRUGIfosfamide

DRUGCarboplatin

RADIATIONRadiotherapy

DRUGThiotepa

DRUGMelphalan

Study design

Allocation

Intervention model

SINGLE_GROUP

Primary purpose

TREATMENT

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

No minimum to 18 Years

Healthy volunteers

Inclusion criteria

* Patients with unresectable localized high grade soft tissue sarcoma

Exclusion criteria

* Patients with organ dysfunction (ejection fraction, liver function test, creatinine \> CTCAE grade 2)

Design outcomes

Primary

Measure	Time frame
Rate of event free survival	Up to 3 years

Secondary

Measure	Time frame
Rate of adverse events	Up to 3 years

Countries

South Korea

Contacts

Primary ContactKi Woong Sung, MD, PhD

kiwoong.sung@samsung.com82-2-3410-3529

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026